209 related articles for article (PubMed ID: 36087507)
1. NK cell immunometabolism as target for liver cancer therapy.
Wang J; Liu X; Jin T; Cao Y; Tian Y; Xu F
Int Immunopharmacol; 2022 Nov; 112():109193. PubMed ID: 36087507
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.
Cao Y; Wang X; Jin T; Tian Y; Dai C; Widarma C; Song R; Xu F
Signal Transduct Target Ther; 2020 Oct; 5(1):250. PubMed ID: 33122640
[TBL] [Abstract][Full Text] [Related]
3. Targeting Stress Sensor Kinases in Hepatocellular Carcinoma-Infiltrating Human NK Cells as a Novel Immunotherapeutic Strategy for Liver Cancer.
Zecca A; Barili V; Olivani A; Biasini E; Boni C; Fisicaro P; Montali I; Tiezzi C; Dalla Valle R; Ferrari C; Cariani E; Missale G
Front Immunol; 2022; 13():875072. PubMed ID: 35677052
[TBL] [Abstract][Full Text] [Related]
4. Advances in metabolic reprogramming of NK cells in the tumor microenvironment on the impact of NK therapy.
Miao L; Lu C; Zhang B; Li H; Zhao X; Chen H; Liu Y; Cui X
J Transl Med; 2024 Mar; 22(1):229. PubMed ID: 38433193
[TBL] [Abstract][Full Text] [Related]
5. Functional and metabolic targeting of natural killer cells to solid tumors.
Wang J; Matosevic S
Cell Oncol (Dordr); 2020 Aug; 43(4):577-600. PubMed ID: 32488848
[TBL] [Abstract][Full Text] [Related]
6. Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment.
Poznanski SM; Singh K; Ritchie TM; Aguiar JA; Fan IY; Portillo AL; Rojas EA; Vahedi F; El-Sayes A; Xing S; Butcher M; Lu Y; Doxey AC; Schertzer JD; Hirte HW; Ashkar AA
Cell Metab; 2021 Jun; 33(6):1205-1220.e5. PubMed ID: 33852875
[TBL] [Abstract][Full Text] [Related]
7. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A; Biber G; Barda-Saad M
Front Immunol; 2020; 11():275. PubMed ID: 32153582
[TBL] [Abstract][Full Text] [Related]
8. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
9. Metabolic hallmarks of natural killer cells in the tumor microenvironment and implications in cancer immunotherapy.
Yang Y; Chen L; Zheng B; Zhou S
Oncogene; 2023 Jan; 42(1):1-10. PubMed ID: 36473909
[TBL] [Abstract][Full Text] [Related]
10. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Zhang C; Liu Y
Front Immunol; 2020; 11():1295. PubMed ID: 32714324
[TBL] [Abstract][Full Text] [Related]
11. Hepatic Tumor Microenvironments and Effects on NK Cell Phenotype and Function.
Piñeiro Fernández J; Luddy KA; Harmon C; O'Farrelly C
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450598
[TBL] [Abstract][Full Text] [Related]
12. Magnetic-Manipulated NK Cell Proliferation and Activation Enhance Immunotherapy of Orthotopic Liver Cancer.
Jiang H; Fu H; Min T; Hu P; Shi J
J Am Chem Soc; 2023 Jun; 145(24):13147-13160. PubMed ID: 37262421
[TBL] [Abstract][Full Text] [Related]
13. NK Cell Metabolism and Tumor Microenvironment.
Terrén I; Orrantia A; Vitallé J; Zenarruzabeitia O; Borrego F
Front Immunol; 2019; 10():2278. PubMed ID: 31616440
[TBL] [Abstract][Full Text] [Related]
14. The tumor microenvironment drives NK cell metabolic dysfunction leading to impaired antitumor activity.
Tumino N; Nava Lauson CB; Tiberti S; Besi F; Martini S; Fiore PF; Scodamaglia F; Mingari MC; Moretta L; Manzo T; Vacca P
Int J Cancer; 2023 Apr; 152(8):1698-1706. PubMed ID: 36468179
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cells in cancer biology and therapy.
Wu SY; Fu T; Jiang YZ; Shao ZM
Mol Cancer; 2020 Aug; 19(1):120. PubMed ID: 32762681
[TBL] [Abstract][Full Text] [Related]
16. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
17. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy.
Zhang W; Zhao Z; Li F
Mol Immunol; 2022 Apr; 144():58-70. PubMed ID: 35203022
[TBL] [Abstract][Full Text] [Related]
19. Modulating NK cell metabolism for cancer immunotherapy.
Terrén I; Orrantia A; Vitallé J; Astarloa-Pando G; Zenarruzabeitia O; Borrego F
Semin Hematol; 2020 Oct; 57(4):213-224. PubMed ID: 33256914
[TBL] [Abstract][Full Text] [Related]
20. NK Cells in the Tumor Microenvironment.
Guillerey C
Adv Exp Med Biol; 2020; 1273():69-90. PubMed ID: 33119876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
